| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $61.5M | +43.6% |
| SG&A Expense | $32.6M | +53.3% |
| Operating Income | -$104.0M | -62.5% |
| Net Income | -$95.6M | -74.4% |
| EPS (Basic) | -$2.53 | -69.8% |
| EPS (Diluted) | -$2.53 | -69.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $96.0M | -13.2% |
| Short-term Investments | $104.4M | -27.1% |
| Current Assets | $207.5M | -20.4% |
| Total Assets | $258.2M | -22.2% |
| Current Liabilities | $21.4M | +130.6% |
| Total Liabilities | $23.0M | +110.7% |
| Stockholders' Equity | $235.1M | -26.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$72.5M | -68.1% |
| Capital Expenditures | $1.1M | -27.5% |
| Investing Cash Flow | $57.7M | +1513.7% |
| Financing Cash Flow | $654K | -99.3% |
| Free Cash Flow | -$73.6M | -64.8% |